{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:57:59Z","timestamp":1791413879768,"version":"4.3.3"},"reference-count":84,"publisher":"Elsevier","isbn-type":[{"value":"9780443297229","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.irn.2025.08.001","type":"book-chapter","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T11:48:25Z","timestamp":1758109705000},"page":"133-160","source":"Crossref","is-referenced-by-count":3,"title":["Novel treatments for myasthenia gravis"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.irn.2025.08.001_bib1","series-title":"StatPearls [Internet]","article-title":"Early pregnancy loss (spontaneous abortion)","author":"Alves","year":"2023"},{"key":"10.1016\/bs.irn.2025.08.001_bib2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ensci.2019.01.006","article-title":"Eculizumab improved weakness and taste disorder in thymoma-associated generalized myasthenia gravis with -striational antibodies: A case report","volume":"14","author":"Amano","year":"2019","journal-title":"eNeurologicalSci"},{"issue":"2","key":"10.1016\/bs.irn.2025.08.001_bib3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): A phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.08.001_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40262-020-00940-9","article-title":"Pharmacokinetic and pharmacodynamic properties of cemdisiran, an RNAi therapeutic targeting complement component 5, in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria","volume":"60","author":"Badri","year":"2021","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/bs.irn.2025.08.001_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.712572","article-title":"Complement factor d as a strategic target for regulating the alternative complement pathway","volume":"12","author":"Barratt","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"10.1016\/bs.irn.2025.08.001_bib6","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: A phase 2 randomized control trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.08.001_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): A randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.08.001_bib8","unstructured":"Bril, V.,\u00a0Druzdz, A., Grosskreutz, J., Habib, A.A., Mantegazza, R., Sacconi, S., et al. (In press). Rozanolixizumab in generalised myasthenia gravis: Pooled analysis of the phase 3 MycarinG study and two open-label extensions. Journal of Neuromuscular Diseases."},{"key":"10.1016\/bs.irn.2025.08.001_bib9","article-title":"Evaluation of the effect of rozanolixizumab on pregnancy outcomes and pre- and postnatal development in cynomolgus monkeys","volume":"132","author":"Cauvin","year":"2024","journal-title":"Reproductive Toxicology (Elmsford, N. Y.)"},{"key":"10.1016\/bs.irn.2025.08.001_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/muscles3010005","article-title":"Eculizumab as additional rescue therapy in myasthenic crisis","volume":"3","author":"Crescenzo","year":"2024","journal-title":"Muscles"},{"issue":"3","key":"10.1016\/bs.irn.2025.08.001_bib11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JND-190464","article-title":"Retrospective analysis of eculizumab in patients with acetylcholine receptor antibody-negative myasthenia gravis: A case series","volume":"7","author":"Datta","year":"2020","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1016\/bs.irn.2025.08.001_bib12","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood-2019-129865","article-title":"Pozelimab, a human antibody against complement factor C5, demonstrates robust inhibition of alternative complement activity both in normal human serum and in phase I normal healthy volunteers","volume":"134","author":"Devalaraja-Narashimha","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.irn.2025.08.001_bib13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s10072-023-07190-0","article-title":"Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors","volume":"45","author":"Fionda","year":"2024","journal-title":"Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"key":"10.1016\/bs.irn.2025.08.001_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: Differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1016\/bs.irn.2025.08.001_bib15","first-page":"670","article-title":"Corticosteroid dose tapering during treatment with zilucoplan in patients with generalized myasthenia gravis: 120- week Follow-up of RAISE-XT","volume":"70","author":"Freimer","year":"2024","journal-title":"Muscle & Nerve"},{"issue":"17","key":"10.1016\/bs.irn.2025.08.001_bib16","article-title":"Classical pathway inhibition with anti-active C1s antibody DNTH103 prevents neurotransmission impairment in a preclinical model of myasthenia gravis","volume":"102","author":"Gokhale","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.08.001_bib17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jocn.2023.11.013","article-title":"Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study","volume":"119","author":"GomezMancilla","year":"2024","journal-title":"Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia"},{"issue":"7","key":"10.1016\/bs.irn.2025.08.001_bib18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): A prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.08.001_bib19","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.921431","article-title":"Successful transition from plasma exchange to eculizumab in acetylcholine receptor antibody- and muscle-specific kinase (MuSK) antibody-negative myasthenia gravis: A case report","volume":"21","author":"Greenwood","year":"2020","journal-title":"American Journal of Case Reports"},{"issue":"12","key":"10.1016\/bs.irn.2025.08.001_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16490","article-title":"Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"31","author":"Habib","year":"2024","journal-title":"European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies"},{"key":"10.1016\/bs.irn.2025.08.001_bib21","unstructured":"Habib, A.A., Grosskreutz, J., Utsugisawa, K., Vu, T., Vissing, J., Gayfieva, M., et al. (In press).\u00a0Long-term safety of rozanolixizumab in patients with generalised myasthenia gravis: Results from the Phase 3 MycarinG and two open-label extension studies. Journal of Neuromuscular Disorders."},{"key":"10.1016\/bs.irn.2025.08.001_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241273036","article-title":"Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: A subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study","volume":"17","author":"Habib","year":"2024","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"16","key":"10.1016\/bs.irn.2025.08.001_bib23","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"issue":"7_Supplement_1","key":"10.1016\/bs.irn.2025.08.001_bib24","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1212\/01.wnl.0001051900.06940.ea","article-title":"Immune checkpoint inhibitor related myositis\/myasthenia gravis overlap syndrome treated with eculizumab","volume":"103","author":"Hewitt","year":"2024","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2025.08.001_bib25","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1016\/bs.irn.2025.08.001_bib26","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00415-021-10428-6","article-title":"Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19","volume":"268","author":"Hofstadt-van Oy","year":"2021","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.08.001_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle & Nerve"},{"issue":"5","key":"10.1016\/bs.irn.2025.08.001_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurology"},{"issue":"23","key":"10.1016\/bs.irn.2025.08.001_bib29","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.08.001_bib30","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): Interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2023","journal-title":"Frontiers in Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2025.08.001_bib31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2025.08.001_bib32","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/acn3.51376","article-title":"Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: Responder analyses","volume":"8","author":"Howard","year":"2021","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2025.08.001_bib33","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.08.001_bib34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/mus.28044","article-title":"Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study","volume":"69","author":"Howard","year":"2024","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.08.001_bib35","first-page":"562","article-title":"Pozelimab and cemdisiran combination therapy in patients with myasthenia gravis: Phase 3 NIMBLE trial design","volume":"70","author":"Jacob","year":"2024","journal-title":"Muscle & Nerve"},{"issue":"S3","key":"10.1016\/bs.irn.2025.08.001_bib36","article-title":"P782: A phase 2, randomized trial evaluating the safety and efficacy of pozelimab and cemdisiran in patients with paroxysmal nocturnal hemoglobinuria","volume":"7","author":"Jang","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/bs.irn.2025.08.001_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241309431","article-title":"Eculizumab in thymoma-associated myasthenia gravis: A real-world cohort study","volume":"17","author":"Jin","year":"2024","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"10","key":"10.1016\/bs.irn.2025.08.001_bib38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/11593110-000000000-00000","article-title":"Fluoroquinolone-associated myasthenia gravis exacerbation: Evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review","volume":"34","author":"Jones","year":"2011","journal-title":"Drug Safety: An International Journal of Medical Toxicology and Drug Experience"},{"issue":"1","key":"10.1016\/bs.irn.2025.08.001_bib39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.08.001_bib40","article-title":"Design of a phase 3, global, multicenter, randomized, placebo-controlled, double-blind study of nipocalimab in pregnancies at risk for severe hemolytic disease of the fetus and newborn","author":"Komatsu","year":"2024","journal-title":"American Journal of Perinatology"},{"issue":"5","key":"10.1016\/bs.irn.2025.08.001_bib41","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1007\/s00415-024-12234-2","article-title":"Ravulizumab in myasthenic crisis: The first case report","volume":"271","author":"Konen","year":"2024","journal-title":"Journal of Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2025.08.001_bib42","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10875-010-9468-4","article-title":"Neonatal fc receptor: From immunity to therapeutics","volume":"30","author":"Kuo","year":"2010","journal-title":"Journal of Clinical Immunology"},{"issue":"23","key":"10.1016\/bs.irn.2025.08.001_bib43","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2025.08.001_bib44","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","article-title":"Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension","volume":"96","author":"Mantegazza","year":"2021","journal-title":"Neurology"},{"issue":"27","key":"10.1016\/bs.irn.2025.08.001_bib45","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"6","key":"10.1016\/bs.irn.2025.08.001_bib46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.imbio.2015.04.006","article-title":"The membrane attack complex as an inflammatory trigger","volume":"221","author":"Morgan","year":"2016","journal-title":"Immunobiology"},{"issue":"1","key":"10.1016\/bs.irn.2025.08.001_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.08.001_bib48","first-page":"572","article-title":"Safety and effectiveness of ravulizumab in generalized myasthenia gravis: Evidence from a global registry","volume":"70","author":"Narayanaswami","year":"2024","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.08.001_bib49","first-page":"710","article-title":"Safety outcomes in pregnant patients treated with the complement 5 inhibitor therapy (C5IT) eculizumab","volume":"70","author":"Narayanaswami","year":"2024","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1016\/bs.irn.2025.08.001_bib50","article-title":"Immune checkpoint Inhibition-related myasthenia-myositis-myocarditis responsive to complement blockade","volume":"11","author":"Nelke","year":"2024","journal-title":"Neurology\u00ae Neuroimmunology & Neuroinflammation"},{"key":"10.1016\/bs.irn.2025.08.001_bib51","first-page":"574","article-title":"Concomitant corticosteroid use with ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: Phase 3 CHAMPION-MG open label extension final results","volume":"70","author":"Nicolle","year":"2024","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.08.001_bib52","first-page":"696","article-title":"Change in concomitant immunosuppressive therapies for generalized myasthenia gravis in patients receiving complement C5 inhibitor therapies: A retrospective analysis of registry data","volume":"70","author":"Nowak","year":"2024","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.08.001_bib53","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2501561","article-title":"MINT investigators. A phase 3 trial of inebilizumab in generalized myasthenia gravis","author":"Nowak","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1016\/bs.irn.2025.08.001_bib54","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific b cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor t cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nature Biotechnology"},{"issue":"12","key":"10.1016\/bs.irn.2025.08.001_bib55","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: A systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/bs.irn.2025.08.001_bib56","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-024-07972-0","article-title":"Eculizumab as rescue therapy for relapse of myasthenia gravis after immune-checkpoint inhibitors: A case report","author":"Rigamonti","year":"2025","journal-title":"Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"issue":"1","key":"10.1016\/bs.irn.2025.08.001_bib57","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: Predominance of IgG subclasses 1 and 3","volume":"67","author":"Rodgaard","year":"1987","journal-title":"Clinical and Experimental Immunology"},{"issue":"11","key":"10.1016\/bs.irn.2025.08.001_bib58","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nature Biotechnology"},{"issue":"4","key":"10.1016\/bs.irn.2025.08.001_bib59","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","article-title":"Efgartigimod improved health-related quality of life in generalized myasthenia gravis: Results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)","volume":"270","author":"Sacca","year":"2023","journal-title":"Journal of Neurology"},{"issue":"21","key":"10.1016\/bs.irn.2025.08.001_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11216394","article-title":"New targeted agents in myasthenia gravis and future therapeutic strategies","volume":"11","author":"Sanchez-Tejerina","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"7","key":"10.1016\/bs.irn.2025.08.001_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: An update","volume":"10","author":"Sheikh","year":"2021","journal-title":"Journal of Clinical Medicine"},{"issue":"6","key":"10.1016\/bs.irn.2025.08.001_bib62","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/mus.27422","article-title":"Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study","volume":"64","author":"Siddiqi","year":"2021","journal-title":"Muscle & Nerve"},{"issue":"7","key":"10.1016\/bs.irn.2025.08.001_bib63","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/bs.irn.2025.08.001_bib64","unstructured":"Soliris Product Information. Retrieved from Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125166s431lbl.pdf."},{"key":"10.1016\/bs.irn.2025.08.001_bib65","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241261602","article-title":"The safety and efficacy profile of eculizumab in myasthenic crisis: A prospective small case series","volume":"17","author":"Song","year":"2024","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"11","key":"10.1016\/bs.irn.2025.08.001_bib66","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1007\/s00415-022-11222-8","article-title":"Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: A case report","volume":"269","author":"Strano","year":"2022","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.08.001_bib67","article-title":"Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation","volume":"14","author":"Tang","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"17-18","key":"10.1016\/bs.irn.2025.08.001_bib68","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Molecular Immunology"},{"issue":"11","key":"10.1016\/bs.irn.2025.08.001_bib69","article-title":"Successful control of myasthenic crisis after the introduction of ravulizumab in myasthenia gravis: A case report","volume":"16","author":"Uchi","year":"2024","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/bs.irn.2025.08.001_bib70","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.irn.2025.08.001_bib71","unstructured":"Ultomiris-Product Information. Retrieved from Available at https:\/\/alexion.com\/Documents\/Ultomiris_USPI.pdf."},{"key":"10.1016\/bs.irn.2025.08.001_bib72","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420932035","article-title":"Eculizumab as a promising treatment in thymoma-associated myasthenia gravis","volume":"13","author":"Velez-Santamaria","year":"2020","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"6","key":"10.1016\/bs.irn.2025.08.001_bib73","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mus.28277","article-title":"Efgartigimod alfa-fcab use in a pregnant woman with generalized myasthenia gravis: A case report","volume":"70","author":"Verity","year":"2024","journal-title":"Muscle & Nerve"},{"issue":"10","key":"10.1016\/bs.irn.2025.08.001_bib74","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1007\/s10072-023-06900-y","article-title":"Starting eculizumab as rescue therapy in refractory myasthenic crisis","volume":"44","author":"Vinciguerra","year":"2023","journal-title":"Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"issue":"7","key":"10.1016\/bs.irn.2025.08.001_bib75","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","article-title":"Minimal symptom expression\u2019 in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"Vissing","year":"2020","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.08.001_bib76","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000511957","article-title":"Eculizumab during pregnancy in a patient with treatment-refractory myasthenia gravis: A case report","volume":"13","author":"Vu","year":"2021","journal-title":"Case Reports in Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.08.001_bib77","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evidence"},{"issue":"14","key":"10.1016\/bs.irn.2025.08.001_bib78","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.08.001_bib79","first-page":"616","article-title":"Concomittant intravenous immunoglobulin or plasma exchange has no effect on complement inhibition by zilucoplan","volume":"70","author":"Weiss","year":"2024","journal-title":"Muscle & Nerve"},{"issue":"4","key":"10.1016\/bs.irn.2025.08.001_bib80","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs placebo for generalized myasthenia gravis: A randomized clinical trial","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.08.001_bib81","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1002\/mus.26124","article-title":"Eculizumab in refractory myasthenic crisis","volume":"58","author":"Yeo","year":"2018","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1016\/bs.irn.2025.08.001_bib82","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/mus.28037","article-title":"Novel uses of complement inhibitors in myasthenia gravis-two case reports","volume":"69","author":"Zadeh","year":"2024","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.08.001_bib83","unstructured":"Zilbrisq-Product Information. Retrieved from\u00a0Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216834s000lbl.pdf."},{"issue":"10","key":"10.1016\/bs.irn.2025.08.001_bib84","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nature Reviews. Immunology"}],"container-title":["International Review of Neurobiology","Myasthenia Gravis, Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:57:51Z","timestamp":1760500671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774225000947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443297229"],"references-count":84,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2025.08.001","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}